The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028, the State Department announced Thursday.
Gilead Sciences had already announced it would sell that supply of the protective drug lenacapvir at no profit for use in low- and middle-income countries that are hard-hit by HIV. The question was who would buy and distribute them after the Trump administration slashed foreign aid earlier this year – forcing closures of health clinics and disrupting HIV testing and care in many countries.
